Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;2(4):327-31.
doi: 10.1007/s13193-012-0140-8. Epub 2012 Mar 8.

Systemic therapy in soft tissue sarcomas: past, present and future

Samit Purohit  1 , Rohan Bhise, Sandhya Appachu, K C Lakshmaiah, K Govindbabu
Affiliations

Systemic therapy in soft tissue sarcomas: past, present and future

Samit Purohit et al. Indian J Surg Oncol. 2011 Dec.

Abstract

Soft tissue sarcomas (STS) comprise 1% of all cancers diagnosed worldwide with more than 40 different histological subtypes each with distinct underlying biology, natural history and response to treatment. Due to the differential chemosensitivity it is imperative to have a correct histological diagnosis for optimal treatment of these patients. Even though surgery remains the primary modality of treatment there is increasing specialization of chemotherapy with respect to histological subtype. In general there is no place for "one size fits all strategy". To correctly define the role of chemotherapy, an extensive search was carried out online and offline for all relevant articles concerning chemotherapy in soft tissue sarcoma. This review aims to discuss the evolution of chemotherapy, its present role in neoadjuvant, adjuvant, metastatic settings and exciting trends with the advent of targeted therapies.

Keywords: Adjuvant chemotherapy; Soft tissue sarcoma; Trabectedin.

PubMed Disclaimer

References

    1. Benjamin R, Pisters Peter WT, Helman LJ, Bramwell Vivien HC, Rubin BP, O’Sullivan B. Sarcomas of soft tissue. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKeena WG, editors. Clinical oncology. 4. Philadelphia: Churchill Livingstone Elsevier; 2008. pp. 2009–2056.
    1. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CyVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537–1545. - PubMed
    1. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007;25:3144–3150. doi: 10.1200/JCO.2006.09.7717. - DOI - PubMed
    1. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, Members of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008;34:339–347. doi: 10.1016/j.ctrv.2008.01.005. - DOI - PubMed
    1. Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG, et al. Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control. Strahlenther Onkol. 1999;175:259–266. doi: 10.1007/BF02743576. - DOI - PubMed

LinkOut - more resources